CIBINQO (abrocitinib)

For the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with systemic drug products, including biologics, or when use of those therapies is inadvisable.1

Image Corners
Rounded
Group
Open

Powerful Skin Clearance and Rapid Itch Relief

EASI-75 at week 12 and PP-NRS4 as early as week 2 achieved for some patients

See Efficacy Data

Flexibility to Increase Dose if Needed

CIBINQO is an oral, once-daily treatment option1:

  • 100 mg recommended dose
  • 200 mg may be considered for patients uncontrolled on 100 mg after 12 weeks

Discontinue therapy if an adequate response is not achieved on 200 mg

See Dosing

Well-studied Safety Profile in AD Population

Studied in 3582 patients with AD across multiple clinical trials

See Safety Information

Group
Close

Request a Product Representative

Have a product question? Request a call from your product representative

Request a Call

Group
Open

Explore Our Coverage and Patient Support

Assisting with access and affordability for patients prescribed CIBINQO

Start Now

Copay Savings Card

Help eligible, commercially insured patients with access to co-pay savings*

See Savings Offer and Terms

*Limits, terms, and conditions apply.
Group
Close
AD=atopic dermatitis; EASI-75=≥75% improvement in lesion extent and severity from baseline on the Eczema Area and Severity Index; PP-NRS4=≥4-point reduction from baseline on the Peak Pruritus Numerical Rating Scale.

+DIVIDER+

References:

1 CIBINQO Package insert. Pfizer Inc; 2023.

2 Data on file. Pfizer Inc; New York, NY.

3 Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863-873.

4 Simpson EL, Silverberg JI, Nosbaum A, et al. Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2
years. Poster P0362. Presented at: European Academy of Dermatology and Venereology Hybrid Congress; September 7-10, 2022.